Stock Research: Harvard Bioscience

Peer-based, data-driven stock research by Obermatt enables quick and easy due diligence for your stock investing.

What's New

Recent improvements to enhance your investment research experience

360° View free for everyone

Our most comprehensive analysis—the 360° View—is now free for everyone. To maintain our research quality, other ranks are now part of our new subscription plans.

3 new subscription models

Plans for every investor - from stock ideas to in-depth analysis.

Similar Stocks

Four stock alternatives to the stock you're searching.

Harvard Bioscience

NasdaqGM:HBIO US4169061052
1
  • Value
    4
  • Growth
    3
  • Safety
    Safety
    97
  • Combined
    13
  • Sentiment
    11
  • 360° View
    360° View
    1
Unlock
Which ranks are driving this 360° View?
Subscribe to View
Company Description

Harvard Bioscience develops and sells technologies for life science applications. It operates in the life science research, drug discovery, and preclinical testing industries and includes brands such as Harvard Apparatus, DSI, and Panlab. The company sells globally to academic institutions, government laboratories, and pharmaceutical companies. In the last fiscal year, the company had a market cap of $17 million, profits of $55 million, and revenue of $94 million, with 330 employees.

more
Analysis

ANALYSIS: With an Obermatt 360° View of 1 (better than 1% compared with alternatives), overall professional sentiment and financial characteristics for the stock Harvard Bioscience are critical, mostly below average. The 360° View is based on consolidating four consolidated indicators, with three out of four indicators below average for Harvard Bioscience. Only the consolidated Value Rank has an attractive rank of 97, which means that the share price of Harvard Bioscience is on the lower side compared with the typical size in indicators such as revenues, profits, and invested capital. This means that the stock price is lower than for 97% of alternative stocks in the same industry. All other consolidated ranks are below average. The consolidated Growth Rank has a low rank of 3, which means that the company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, and invested capital growth as well as stock returns. The consolidated Safety Rank has a riskier rank of 4, meaning the company has a riskier financing structure than 96% comparable companies when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. Finally, professionals are more pessimistic about the stock than for 89% of alternative investment opportunities, reflected in the consolidated Sentiment Rank of 11. ...read more

more
Index
NASDAQ
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 21-Aug-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
97 95 74 97
Growth
3 1 97 55
Safety
Safety
4 61 22 31
Sentiment
11 25 28 11
360° View
360° View
1 49 61 45
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
23 80 87 64
Opinions Change
15 50 11 50
Pro Holdings
n/a 14 41 17
Market Pulse
1 8 31 2
Sentiment
11 25 28 11
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
97 95 74 97
Growth
3 1 97 55
Safety Safety
4 61 22 31
Combined
13 52 77 73
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
97 93 84 96
Price vs. Earnings (P/E)
98 94 75 93
Price vs. Book (P/B)
100 86 47 64
Dividend Yield
1 1 1 1
Value
97 95 74 97
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
43 12 50 25
Profit Growth
10 1 84 86
Capital Growth
23 63 98 5
Stock Returns
3 9 100 95
Growth
3 1 97 55
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
30 35 26 24
Refinancing
1 75 43 57
Liquidity
28 42 34 39
Safety Safety
4 61 22 31

Similar Stocks

Discover high‑ranked alternatives to Harvard Bioscience and broaden your portfolio horizons.

Micron

NasdaqGS:MU
Country: USA
Industry: Semiconductors
Size: X-Large
Full Stock Analysis

Meta

NasdaqGS:FB
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Alphabet

NasdaqGS:GOOG.L
Country: USA
Industry: Interactive Media & Services
Size: XX-Large
Full Stock Analysis

Lithia Motors

NYSE:LAD
Country: USA
Industry: Automotive Retail
Size: X-Large
Full Stock Analysis

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.